• The primary efficacy endpoint is the change from baseline to the week 8 endpoint in the 17-item HAM-D total score [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  

• mean change from baseline in the Young Mania Rating Scale [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  
• mean change from baseline in the Montgomery-Asberg Depression Rating Scale [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  
• percentage of subjects with Clinical Global Inventory (CGI) global improvement score of 1 or 2 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  
• mean change from baseline in the CGI-severity of illness score at study endpoint [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  
• mean change from baseline in the total score of the Quality of Life Enjoyment and Satisfaction Questionnaire [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  
• mean change from baseline in the total score of the Beck Depression Inventory [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  

Drug: ziprasidone HCl (Geodon)
Oral dose of Geodon up to 60mg BID.

Bipolar II disorder is largely unstudied, with much less known about its treatment in comparison to Bipolar I disorder. While established mood stabilizers treat and prevent subsequent episodes of hypomania, chronic or recurrent depressions are harder to treat or prevent. In general the treatment of depression in Bipolar II patients is often complicated and there is no clinical unanimity on what approaches to follow. Administration of proven antidepressants would seem most appropriate and are most often used, but their use often involves a number of difficulties. Among these are:

• antidepressant efficacy is established for unipolar patients and extrapolation to Bipolar II patients is done without empirical support
• Bipolar II patients can have switches into hypomanic behavior in response to antidepressant treatment given as monotherapy
• even when mood stabilizers are concomitantly given, switches to hypomanic states still occur when antidepressants are added
• antidepressants can cause cycle acceleration or induce rapid cycling when given to Bipolar II patients
• non-response and loss of response are common reactions to antidepressants in Bipolar II patients

This study will also assess the tolerability of Geodon in the treatment of patients diagnosed with Bipolar II disorder who currently meet criteria for a Major Depressive Episode by examining the incidence of adverse events and the withdrawal rate due to adverse events.

This will be an open-label study. Subjects will be treated for 8 weeks with Geodon, starting at a dose of 20 mg twice per day. The maximum dose will be 60 mg twice per day. Subjects will have a physical exam, electrocardiogram (ECG), standard laboratory tests and a urine drug screen at the screen visit.

Efficacy evaluations will include 17-item Hamilton Depression Scale, Hamilton Anxiety Scale (HAM-D), Montgomery-Asberg Depression Rating Scale, and the Young Mania Rating Scale. Social outcome will be measured with a quality-of-life scale (the Q-LES-Q). Overall efficacy will be rated using the Clinical Global Severity and Improvement Scales.